Premium
The Evaluation of Statins as Potential Inhibitors of the LEDGF/p75–HIV‐1 Integrase interaction
Author(s) -
Harrison Angela T.,
Kriel Frederik H.,
Papathanasopoulos Maria A.,
Mosebi Salerwe,
Abrahams Shaakira,
Hewer Raymond
Publication year - 2015
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.12384
Subject(s) - integrase , pravastatin , chemistry , lovastatin , lipophilicity , recombinant dna , integrase inhibitor , in vitro , human immunodeficiency virus (hiv) , biochemistry , pharmacology , virology , biology , antiretroviral therapy , cholesterol , dna , viral load , gene
Lovastatin was identified through virtual screening as a potential inhibitor of the LEDGF /p75– HIV ‐1 integrase interaction. In an AlphaScreen assay, lovastatin inhibited the purified recombinant protein–protein interaction ( IC 50 = 1.97 ± 0.45 μ m ) more effectively than seven other tested statins. None of the eight statins, however, yielded antiviral activity in vitro , while only pravastatin lactone yielded detectable inhibition of HIV ‐1 integrase strand transfer activity (31.65% at 100 μ m ). A correlation between lipophilicity and increased cellular toxicity of the statins was observed.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom